ICAAC In Brief: SmithKline Beecham Famvir
Executive Summary
SmithKline Beecham Famvir: Famciclovir delays recurrent episodes of genital herpes in patients with frequently recurring disease who received 250 mg twice-daily doses of the antiviral for one year, according to results from a 455-patient trial presented at ICAAC. Median time to first clinically confirmed lesional episodes for patients treated with Famvir in the study was 11 months compared to 1.5 months for placebo-treated patients. Median time to first culture documented recurrence was more than one year for patients receiving Famvir and 2.7 months for patients on placebo...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth